Apply!
Apply today to the PSCC and benefit from the PSCC offer. Applications are evaluated on a rolling basis as they come in. Through the Support and Orientation Office (SOO) team, the cluster provides you access to all the resources that condition the success of innovation in oncology: talents, technologies, network, financing, spaces, patients and associated data.​ By vocation and by culture, the PSCC brings together disciplines (biology, mathematics, physics, artificial intelligence, etc.) and fields of application (therapeutics, diagnostics, medical devices, digital health).
For who ?
We enthusiastically invite projects from a wide range of companies, from start-ups to mature companies, encompassing both those in the nascent preclinical stage and those advancing through early clinical phases. These projects span the entire oncology landscape and include a wide range of innovative solutions: therapies, diagnostics, and medical devices. We support French as well as international companies contributing to the French economy.
A selective approach
The PSCC concentrates its resources where it can make a difference, that is on projects (ideation, creation, pre-seed, seed, acceleration) that are scientifically creative and have very high diagnostic or therapeutic potential. To capture the best of discovery and innovation, it relies on a rigorous selection process and an independent evaluation committee made up of experienced scientists and entrepreneurs. Depending on their ranking, the selected projects benefit from all or part of the PSCC's offer.
"If your project is selected, the role of the Support and Orientation Office (SOO) will be to coach and support your team, to coordinate interactions with the partners scientific offer and to facilitate connections with experts and potential partners.
Contact us to know more about our offer, expertise and platforms as they are deployed."
Lucie Mondoulet, PhD. Member of the SOO
To apply
Fill out the form (link below) and upload your presentation.
​
Each applicant project must provide a powerpoint/PDF file in English, including the following non-confidential elements:
-
Slide 1: Summary - synthetic presentation of the project
-
Slide 2: The problem/medical need addressed by the project
-
Slide 3: The solution and its innovativeness - explain the rationale and level of validation of the project (bibliographic support and/or data generated)
-
Slides 4-6: The science behind the solution - provide results, give full details on experimental protocols, include bibliographical references:
-
For MDs: preclinical and/or clinical study(s)
-
For therapeutics: validation(s) of the mechanism of action, and/or efficacy data (in vitro, and/or ex vivo and/or in vivo), and/or clinical study(s), if applicable.
-
-
Slide 7 : Intellectual property - current/upcoming patents (references), licenses, freedom to operate...
-
Slide 8: Management team, founders and strategic/scientific advisors - with details on previous experience (company names...), and key positions to be recruited if applicable
-
Slide 9: Roadmap - Gantt Chart type: milestones achieved and those to come, with key milestones (“scientific advice”, clinical batch manufacturing, IND, CE marking, etc.). Mention amounts raised to date and those to come.
-
Slide 10 : Competitive landscape and project differentiators - identify competitors and highlight the project's points of differentiation.
-
Slide 11: Support to date - SATT, incubator, advisors, etc.
-
Slide 12: Expectations and commitments towards the PSCC
-
Slide 13 (for projects not located in France only) : Development plan in France: How and when do you plan to develop your presence in France?
-
Possible appendices - additional scientific and/or medical information
Note: please quote your sources and spell out acronyms.
​
The SOO may contact you to obtain additional information based on your request.
Our selection criteria
Your application will be processed by the SOO and evaluated by an independent committee,taking into account the project's maturity.
Aim: identify the projects that have the most potential for acceleration by the PSCC.